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 ABSTRACT 
Background: Current guidelines warn from potential electromagnetic interferences 
(EMI) when using bioelectrical impedance analysis (BIA) to measure body composition 
in patients equipped with implantable cardioverter-defibrillators (ICD). We aimed to test 
the occurrence of EMI in a setting where this risk was experimentally maximized.  
 
Material & Methods: Outpatients scheduled for routine ICD controls underwent at the 
same time a BIA measurement using an electrical current of 0.8 mAmp at frequencies 
from 5 to 100 KHZ. ICD sensitivity levels were set to maximum levels while therapies 
were temporarily inactivated. The device electrograms were monitored in real-time to 
detect sensed and/or visible EMI during BIA measurement.   
 
Results: A total of 63 patients equipped with single- (n=13), dual-chambers (n=18) or 
biventricular (n=32) ICDs from 5 major manufacturers were included. No EMI were 
detected by the ICDs in these patients, nor were any artefacts visualized during real-time 
electrogram recordings. 
 
Conclusion: BIA can be safely performed in patients equipped with ICDs without 
cardiac monitoring. Current guidelines should be updated accordingly. 
 
 
 CLINICAL RELEVANCY STATEMENT 
Measurement of body composition by bioelectrical impedance analysis (BIA) is 
particularly indicated in patients at risk of malnutrition such as those with chronic heart 
failure (HF). However there is a fear of potential electromagnetic interferences (EMI) 
between BIA and implantable cardioverter defibrillators (ICDs) that are often used in this 
population. Our findings confirm the absence of EMI between ICD and BIA. Body 
composition assessment by BIA using frequencies from 5 to 100 KHZ can therefore be 
safely performed without cardiac monitoring in patients equipped with ICDs. 
 
 
  
INTRODUCTION 
Bioelectrical impedance analysis (BIA) is a well validated, non-invasive and relatively 
inexpensive technique to measure body composition and improve nutritional status 
assessment.1 A comprehensive nutritional assessment is particularly indicated in patients 
at risk of malnutrition or weight loss, such as those suffering from chronic diseases 
including heart failure (HF).2 About 10 to 15% of patients with chronic HF in New York 
Heart Association (NYHA) classes II to IV are affected with the most severe form of 
body wasting named cardiac cachexia, which is a major predictor of poor clinical 
outcomes.3, 4 Cardiac cachexia has been defined as ≥5% of body weight loss in ≤12 
months or a body mass index (BMI) < 20 kg/m2 in association with several other criteria 
including low fat-free mass index (FFMI), which can be measured by BIA.5   
Depending on the country, it is estimated that 25 to 46% of patients with chronic 
HF followed by HF specialists in Europe have an indication for an implantable 
cardioverter defibrillator (ICD) associated or not with cardiac resynchronisation therapy 
(CRT).6 Therefore BIA is expected to be performed in a significant number of HF 
patients equipped with ICDs. However, BIA manufacturers7 and current nutrition 
guidelines2 warn from possible electromagnetic interferences (EMI) between ICDs and 
BIA, which is a significant barrier for its use. Indeed EMI may lead to oversensing 
resulting in potentially serious complications including inappropriate shocks and 
inhibition of pacing. To our knowledge the risk of potential EMI was tested only in a 
single small study that required further assessment.8 Therefore, we aimed to prospectively 
evaluate the potential risk of EMI between BIA and ICDs in a larger number of patients 
and in a setting where the risk of EMI was experimentally maximised. 
 
 
 METHODS 
Study design and patients 
This was a single-center prospective study examining potential EMI between BIA and 
ICDs. During 3 months, consecutive outpatients scheduled for routine ICD controls at the 
device clinic of the Geneva University Hospitals were included in the study. Patients who 
were pacemaker-dependent or aged < 18 years were excluded from the study. As there 
were no previous reports of EMI between ICDs and BIA in the literature we could not 
calculate a sample size for our study. We tested the hypothesis that there would be no 
EMI detected between BIA and ICD in a larger population equipped with a wider range 
of different ICD manufacturers and models compared to previous studies. During ICD 
interrogation by a cardiologist (LPM) all patients underwent body composition 
measurements using BIA by a specifically trained Ph.D. student (AMM). This protocol 
was approved and accepted as part of a quality control study by the Geneva University 
Hospitals Ethics Committee. All subjects volunteered for the study. 
 
ICD interrogation 
A standard ICD control was first performed to rule out device dysfunction, and the 
intracardiac electrogram (EGM) evaluated for baseline noise. Then, the sensitivity levels 
of the ICD were set to the maximum level while ICD therapies were temporarily 
inactivated in order to maximize the risk of EMI with BIA. At each frequency of the BIA 
current, EGMs were monitored in real-time to detect sensed and/or visible EMI (Figure 
1). An EMI was defined as the detection of unexpected signals due to the action of the 
electrical field. Presence of new artefacts visible on the real-time EGM during BIA, but 
 
 
 undetected by the device, were also noted. To verify the absence of EMI, EGMs and 
device marker channels were saved and printed for analysis during the entire BIA 
measurement. At the end of the experiment, the sensitivity levels were reprogrammed to 
their initial settings and the ICD therapies were reactivated. 
BIA measurement 
After skin cleaning with 70% ethanol 4 adhesive electrodes (3M Red Dot T, 3M Health 
Care, Borken, Germany) were placed on the dorsal side of the left hand, left wrist, left 
foot, and left ankle while the patient was lying supine with hand palms facing inwards. 
An electrical current of 0.8 mAmp was produced successively at 3 different frequencies 
(5, 50, 100 KHz) by a generator/analyser (Nutriguard M, DataInput, Gmbh, Darmstadt, 
Germany) during approximately 2 minutes to measure whole-body resistance and 
reactance.1   
 
Data collection and statistical analysis 
On the day of the ICD control, each patient was questioned about symptoms for 
determination of NYHA class and weight changes during the previous year. Weight, 
height and vital signs were measured. Body Mass Index (BMI) was calculated as weight 
(kg) divided by squared height (m2). Information on ICD type, implant date and 
indication as well as etiology of heart disease and left ventricular ejection fraction 
(LVEF) were retrieved from the Geneva University Hospitals electronic medical record. 
 Descriptive statistics were assessed and results expressed as mean ± standard 
deviation (SD) for continuous variables and number of patients (%) for categorical 
variables.  
 
 
 RESULTS   
We included 63 patients (54 men) with a mean age of 64.8 ± 14.6 years, mean LVEF of 
32.1 ± 16.5% and mean BMI of 27.9 ± 4.8 kg/m2. Primary prevention was the main ICD 
indication (62%), a CRT being implanted in more than half of the patients. Other 
patients’ characteristics are detailed in Table 1. The different ICD manufacturers and 
models are listed in Table 2. Five major companies were represented: Medtronic (n=20), 
Boston scientific (n=15), St-Jude (n=13), Biotronik (n=11), Sorin Group (n=4). Table 3 
details the maximum programmable sensitivity for right atrial, right ventricular and left 
ventricular electrodes according to each manufacturer.  
No EMI were detected by the ICDs during BIA measurements assessed at three 
current frequencies in the 63 participants.  Further, no artefacts were visualized during the 
EGM recordings in any of the ICDs. (Figure 1, Table 2).   
 
DISCUSSION  
In this prospective study including a wide range of different ICD manufacturers and 
models we did not detect any interference between BIA and ICDs even if this risk was 
experimentally maximized. Our study thus demonstrates that BIA using an electrical 
current of 0.8 mAmp at frequencies from 5 to 100 KHZ can safely be performed without 
cardiac monitoring in patients equipped with ICDs. This finding is particularly important 
for the management of patients with severe chronic HF implanted with ICDs who may 
present undernutrition or cardiac cachexia and benefit from targeted nutritional 
interventions.  
 
 
 Electromagnetic fields generated by an electrical current passing through an 
electrically operated device may produce EMI with ICDs. However the high frequencies 
used to assess body composition by BIA (5, 50, 100 kHz) are attenuated by band-pass 
filters that are centered around the physiological frequencies of endocavitary signals (20-
60Hz). In addition, pacemakers and ICD filters are equipped with ceramic feedthrough 
filters that further attenuate EMI in the 30 MHz-10 Ghz range). These filters provide 
protection from high-frequency signals generated by devices such as cell phones, 
microwave ovens and radars (450 MHz to 12 GHz).9, 10 
Buch et al. investigated the impact of BIA measurement on ICDs in 20 patients 
with HF using one type of BIA monitor at three different frequencies (5, 50 and 500 
KHz) and found no EMI.8 Our study differs from this previous report in two main 
respects. First, our sample size is more than 3 times larger including 29 ICD types from 5 
different manufacturers. Second, to maximize the risk of EMI with BIA, we programmed 
the sensitivity levels of the ICD to the maximum level and placed the BIA electrodes on 
the left side of the body (as close as possible to the pulse generator). For these reasons we 
believe that our study now provides confirmation that there is negligible risk of using 
BIA in patients equipped with ICDs.    
BIA is a well validated and easy-to-use method to measure body composition as 
part of a comprehensive nutritional assessment. BIA allows the determination of fat-free 
mass (FFM), body fat (BF), body cell mass (BCM), and total body water (TBW). FFMI 
calculated as the ratio of FFM to squared height is now part of the novel definition of 
cachexia.5 Cardiac cachexia is associated with a 2-3 fold increase in mortality compared 
to non-cachectic patients, which corresponds to a 20 to 40% one-year mortality.3, 4 
 
 
 Further studies are urgently needed to better understand the pathophysiology of cardiac 
cachexia and to develop novel treatments.4, 11, 12 A comprehensive nutritional assessment 
using BIA in the most severe HF patients often implanted with ICDs will be important in 
future trials, some of which being already under way (ClinicalTrials.gov identifier: 
NCT01864733).  
Several limitations need to be considered. First, even if the largest to date, our 
study only tested 63 patients and our results cannot be generalized to all ICDs available 
on the market. However we included different models of the five main ICD 
manufacturers and maximized the risk of EMI in our protocol. Therefore we believe that 
the risk of EMI can be considered as negligible for all ICDs and pacemakers (which are 
equipped with similar filters as ICDs, and have lower sensitivity settings). Second, we 
used a generator producing current frequencies of 5, 50 and 100 KHz and cannot exclude 
potential EMI with BIA devices that may use other frequency regimens such as pulsing at 
lower frequencies that may be detected by devices.  
 
CONCLUSION 
To conclude, our study confirms the absence of EMI between BIA and ICD. Body 
composition assessment by BIA using frequencies from 5 to 100 KHZ can therefore be 
safely performed without cardiac monitoring in patients equipped with ICDs. Current 
nutrition guidelines should be updated accordingly.  
 
 
  
Acknowledgements 
The authors gratefully thank Mrs Nicole Schaerer, Béatrice Sanchez and Carine Stettler 
for their help to recruit patients and all the technicians of the Cardiology Service who 
participated in the ICD controls.  
 
Conflict of Interest disclosures 
The authors report no conflicts of interest. 
 
Funding support 
This study did not receive any external funding.  
 
 
 
  
References 
1. Kyle UG, Bosaeus I, De Lorenzo AD, et al. Bioelectrical impedance analysis--
part i: Review of principles and methods. Clin Nutr. 2004;23:1226-1243. 
2. Kyle UG, Bosaeus I, De Lorenzo AD, et al. Bioelectrical impedance analysis-part 
ii: Utilization in clinical practice. Clin Nutr. 2004;23:1430-1453. 
3. Anker SD, Laviano A, Filippatos G, et al. Espen guidelines on parenteral 
nutrition: On cardiology and pneumology. Clin Nutr. 2009;28:455-460. 
4. von Haehling S, Anker SD. Prevalence, incidence and clinical impact of cachexia: 
Facts and numbers-update 2014. J Cachexia Sarcopenia Muscle. 2014;5:261-263. 
5. Evans WJ, Morley JE, Argiles J, et al. Cachexia: A new definition. Clin Nutr. 
2008;27:793-799. 
6. John Camm A, Nisam S. European utilization of the implantable defibrillator: Has 
10 years changed the 'enigma'? Europace. 2010;12:1063-1069. 
7. Http://www.Data-input.De/media/pdf_english_2014/instructions-for-use-nutriguard-
ms.Pdf.  
8. Buch E, Bradfield J, Larson T, Horwich T. Effect of bioimpedance body 
composition analysis on function of implanted cardiac devices. Pacing Clin 
Electrophysiol. 2012;35:681-684. 
9. Beinart R, Nazarian S. Effects of external electrical and magnetic fields on 
pacemakers and defibrillators: From engineering principles to clinical practice. 
Circulation. 2013;128:2799-2809. 
10. Hayes DL, Wang PJ, Reynolds DW, et al. Interference with cardiac pacemakers 
by cellular telephones. N Engl J Med. 1997;336:1473-1479. 
11. von Haehling S, Anker SD. Treatment of cachexia: An overview of recent 
developments. Int J Cardiol. 2015;184:736-742. 
12. von Haehling S, Lainscak M, Springer J, Anker SD. Cardiac cachexia: A 
systematic overview. Pharmacol Ther. 2009;121:227-252. 
 
 
 
 
 
  
Figure legends 
 
 
 
Figure 1. Examples of real-time electrogram printouts of a biventricular defibrillator at 
baseline and during exposure to BIA at various frequencies. Note the absence of visible 
 
 
 or sensed artefacts on any of the channels (atrial on the top, right ventricle in the middle 
and the far-field can to right ventricular coil on the bottom tracings). 
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